此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (GATEWAY)

2026年5月9日 更新者:Chen Chunyan、Sun Yat-sen University

Neoadjuvant Becotatug Vedotin (Anti-EGFR ADC) Combined With Pucotenlimab (Anti-PD-1) in Patients With Resectable Recurrent Head and Neck Squamous Cell Carcinoma Who Progressed on Prior PD-1/PD-L1 Inhibitor and Platinum-Based Therapy: A Prospective, Single-Arm, Multi-Center, Phase II Clinical Trial

This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1 monoclonal antibody) in patients with resectable recurrent head and neck squamous cell carcinoma (rHNSCC) who have progressed on prior PD-1/PD-L1 inhibitor and platinum-based therapy.

A total of 42 EGFR-positive patients will be enrolled using Simon's two-stage design across 11 centers in China (Stage 1: 25 patients; Stage 2: 17 additional patients with 5% dropout). Enrolled patients will receive 3 cycles of neoadjuvant becotatug vedotin (2.3 mg/kg, IV, Q3W) plus pucotenlimab (3 mg/kg, IV, Q3W), followed by salvage surgery (3-4 weeks later), adjuvant radiotherapy +/- chemotherapy per NCCN/CSCO guidelines, and pucotenlimab maintenance therapy (3 mg/kg, Q3W) for up to 12 cycles or until disease progression or unacceptable toxicity.

The primary endpoint is major pathological response (MPR) rate. The null hypothesis MPR rate is 14% (historical data) and the target MPR rate is 30% (alpha=0.05, power=0.8, one-sided). Secondary endpoints include objective response rate (ORR), pathological complete response (pCR), survival outcomes, quality of life, and safety.

研究概览

详细说明

Recurrent head and neck squamous cell carcinoma (rHNSCC) remains a significant clinical challenge, with recurrence rates of 40-60% after curative treatment. Salvage surgery is the standard of care, yet approximately 50% of patients experience re-recurrence within 2 years. For patients who have progressed on prior PD-1 inhibitor and platinum-based therapy, effective treatment options are extremely limited.

Becotatug vedotin is a novel anti-EGFR antibody-drug conjugate (ADC) that has demonstrated significant anti-tumor activity in HNSCC, with an ORR of 40% in Phase Ia/Ib and 43% in the post-immunotherapy Phase II study. Pucotenlimab (HX008) is a PD-1 inhibitor with an extended half-life (T1/2 = 21.76 days). Phase I/II data showed the combination achieved ORR of 60% in HNSCC with manageable toxicity.

This study investigates neoadjuvant becotatug vedotin plus pucotenlimab in resectable rHNSCC after immunotherapy progression.

TREATMENT REGIMEN:

  1. Neoadjuvant: Becotatug vedotin 2.3 mg/kg IV + Pucotenlimab 3 mg/kg IV, Q3W, 3 cycles
  2. Surgery: Salvage surgery 3-4 weeks after neoadjuvant completion
  3. Adjuvant: IMRT (60-66 Gy/30f) +/- platinum-based chemotherapy per NCCN/CSCO
  4. Maintenance: Pucotenlimab 3 mg/kg IV Q3W for 12 cycles or until progression/toxicity

Simon's two-stage design: Stage 1 (25 patients, >=3 MPR required) to Stage 2 (17 additional, total 42). H0 MPR=14%, H1 MPR=30% (alpha=0.05, power=0.8).

研究类型

介入性

注册 (估计的)

42

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Chunyan Chen, MD, PhD
  • 电话号码:+86 (020) 87342926

学习地点

    • Guangdong
      • Foshan、Guangdong、中国
        • The First People's Hospital of Foshan
      • Guangzhou、Guangdong、中国
        • Sun Yat-sen University Cancer Center
      • Guangzhou、Guangdong、中国
        • Guangdong Provincial People's Hospital
      • Guangzhou、Guangdong、中国
        • Guangzhou First People's Hospital
      • Guangzhou、Guangdong、中国
        • ZhuJiang Hospital of Southern Medical University
      • Guangzhou、Guangdong、中国
        • The third affiliated hospital of Sun Yat-Sen University
      • Guangzhou、Guangdong、中国
        • Cancer Hospital of Guangzhou Medical University
      • Qingyuan、Guangdong、中国
        • Qingyuan People's Hospital
      • Shantou、Guangdong、中国
        • Cancer Hospital of Shantou University Medical College
      • Shenzhen、Guangdong、中国
        • Shenzhen Second People's Hospital
      • Zhanjiang、Guangdong、中国
        • Affiliated Hospital of Guangdong Medical University
    • Jiangxi
      • Ganzhou、Jiangxi、中国
        • Ganzhou Cancer Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

INCLUSION CRITERIA:

  1. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  2. Age 18-75 years at time of consent
  3. Histologically or cytologically confirmed recurrent head and neck squamous cell carcinoma
  4. Disease progression after prior treatment including both PD-1/PD-L1 inhibitor and platinum-based therapy (combined or sequential)
  5. EGFR protein expression positive by immunohistochemistry (IHC), with no EGFR-targeted therapy within 6 months prior to enrollment
  6. Willing to provide archived tumor tissue or undergo fresh tumor biopsy for EGFR testing
  7. At least one measurable extracranial lesion per RECIST v1.1; previously treated lesions must demonstrate clear progression 3 or more months after last local treatment
  8. Resectable disease with no distant metastasis, as assessed by a multidisciplinary team
  9. Adequate organ function within 7 days prior to enrollment: ANC at least 2.0 x 10^9/L, platelet count at least 100 x 10^9/L; total bilirubin less than 1.5 x ULN, ALT/AST less than 2.5 x ULN; serum creatinine less than 1.5 x ULN
  10. Signed informed consent prior to any study-specific procedures
  11. Life expectancy greater than 3 months
  12. Effective contraception during study and for 6 months after last dose

EXCLUSION CRITERIA:

  1. History of other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ)
  2. Comorbidities requiring long-term immunosuppressive therapy or corticosteroids at immunosuppressive doses
  3. Immunodeficiency or history of organ transplantation (including interstitial pneumonia, hepatitis, nephritis, hyperthyroidism, hypothyroidism)
  4. HIV/AIDS; untreated active hepatitis B (HBV-DNA at least 500 IU/mL); hepatitis C (HCV-RNA above detection limit); or HBV/HCV co-infection
  5. High-dose systemic corticosteroids within 4 weeks prior to enrollment
  6. Pregnant or lactating women; fertile patients not using effective contraception
  7. Laboratory values not meeting inclusion criteria within 7 days
  8. Significantly impaired cardiac, hepatic, pulmonary, renal, or bone marrow function
  9. Severe uncontrolled comorbidities or active infections
  10. Concurrent participation in other clinical trials
  11. Refusal or inability to sign informed consent
  12. Other contraindications to study treatment as determined by the investigator
  13. Psychiatric disorders or mental illness resulting in lack of legal capacity

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Neoadjuvant Becotatug Vedotin + Pucotenlimab
Becotatug vedotin as one of the drugs used in neoadjuvant therapy.
Pucotenlimab as one of the drugs used in neoadjuvant therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Major Pathological Response Rate (MPR)
大体时间:At time of surgery, approximately 12 weeks after enrollment
Proportion of patients with less than or equal to 10% viable tumor cells in the surgically resected specimen after neoadjuvant therapy, assessed by central pathology review.
At time of surgery, approximately 12 weeks after enrollment

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:After 3 cycles of neoadjuvant therapy, approximately 9 weeks
Proportion of patients achieving complete response (CR) or partial response (PR) per RECIST v1.1.
After 3 cycles of neoadjuvant therapy, approximately 9 weeks
Pathological Complete Response Rate (pCR)
大体时间:At time of surgery
Proportion of patients with no residual viable tumor cells in the surgically resected specimen.
At time of surgery
Median Overall Survival (mOS)
大体时间:Up to 60 months from enrollment
Time from enrollment to death from any cause.
Up to 60 months from enrollment
Median Progression-Free Survival (mPFS)
大体时间:Up to 60 months from enrollment
Time from enrollment to disease progression per RECIST v1.1 or death from any cause.
Up to 60 months from enrollment
Duration of Response (DoR)
大体时间:Up to 60 months
Time from first documented CR or PR to disease progression or death.
Up to 60 months
6-Month Progression-Free Survival Rate
大体时间:6 months after end of treatment
Proportion of patients alive without disease progression at 6 months after completion of study treatment.
6 months after end of treatment
12-Month Progression-Free Survival Rate
大体时间:12 months after end of treatment
Proportion of patients alive without disease progression at 12 months after completion of study treatment.
12 months after end of treatment
Incidence of Adverse Events (AEs)
大体时间:Through study completion, up to 90 days after last dose
Safety assessed per NCI CTCAE v5.0. Incidence and severity of all AEs, treatment-emergent AEs, and immune-related AEs.
Through study completion, up to 90 days after last dose
Incidence of Serious Adverse Events (SAEs)
大体时间:Through study completion, up to 90 days after last dose
Incidence of serious adverse events assessed per CTCAE v5.0.
Through study completion, up to 90 days after last dose
Quality of Life - DASS-21
大体时间:Baseline, during treatment, and follow-up through 12 months
Depression, Anxiety, and Stress Scale (21-item version).
Baseline, during treatment, and follow-up through 12 months
Quality of Life - PTGI
大体时间:Baseline and follow-up through 12 months
Post-Traumatic Growth Inventory.
Baseline and follow-up through 12 months
Quality of Life - EORTC QLQ-C30
大体时间:Baseline, during treatment, and follow-up through 12 months
EORTC Quality of Life Questionnaire Core 30.
Baseline, during treatment, and follow-up through 12 months
Stigma Scale
大体时间:Baseline and follow-up through 12 months
Chronic disease stigma assessment.
Baseline and follow-up through 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Xuekui Liu, MD, PhD、Sun Yat-sen University Cancer Center
  • 学习椅:Chunyan Chen, MD, PhD、Sun Yat-sen University Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月1日

初级完成 (估计的)

2027年11月1日

研究完成 (估计的)

2029年5月1日

研究注册日期

首次提交

2026年5月9日

首先提交符合 QC 标准的

2026年5月9日

首次发布 (实际的)

2026年5月15日

研究记录更新

最后更新发布 (实际的)

2026年5月15日

上次提交的符合 QC 标准的更新

2026年5月9日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅